FDA Updates for Week of Feb. 27, 2023
March 4th 2023The FDA has approved Kevzara for an inflammatory rheumatic disease and Skyclarys, the first therapy for rare neuromuscular disease. The agency set an action date for Opdivo for melanoma indication. An advisory committee has supported Pfizer’s RSV vaccine, and Janssen has submitted an NDA for combo tablet for metastatic prostate cancer.
Read More
How CMS CPT Codes Are Assisting Underserved Musculoskeletal Patients
March 3rd 2023Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes focus on musculoskeletal and respiratory conditions and the data collected from patients affected. According to Spira, these codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care.
Watch
Lilly Slashed Its Insulin Prices. Will Sanofi and Novo Nordisk Do the Same?
March 2nd 2023Patient groups and lawmakers such as Sen. Bernie Sanders want Sanofi and Novo Nordisk to follow Eli Lilly's example and reduce the prices of their insulin products. Both companies said they already have programs that bring down the cost.
Read More
One Medical Merges With Amazon to Make Access to Care Easier, Affordable
February 27th 2023Amazon has officially acquired One Medical several months after the merger was first announced in July 2022. Together, the organization will work to help more people get better care, when and how they need it.
Read More
FDA Updates for Week of Feb. 20, 2023
February 25th 2023The FDA approved several new therapies this week, including a weekly hemophilia A treatment, an extended-release version of Austedo, and the first drug for geographic atrophy due to AMD, as well as an accelerated approval to Filspari for rare kidney disease. The agency also indicated it will hold an advisory committee meeting on Onpattro for heart failure indication, granted priority review for Pfizer’s RSV vaccine and for a life-threatening hereditary immune disease, and also set goal date for blurry vision therapy.
Read More
American Cancer Society is Tackling Diversity in Cancer Research With New Training Program
February 21st 2023The American Cancer Society has introduced the American Cancer Society Center for Diversity in Cancer Research Training to address the lack of diversity in research environments. The new center will enhance the traditional academic journey, focusing on meeting potential researchers where they are and helping them overcome barriers to future success.
Read More
Rich Priore of Tulane University Talks Financial Concerns on Healthcare After PHE Expiration
February 16th 2023Rich Priore, Sc.D., M.H.A., a clinical associate professor in the Department of Health Policy and Management at Tulane University addresses how hospitals will be affected on the cost and revenue side after the COVID-19 Public Health Emergency expires May 11.
Watch
Mark Cuban Assails PBMs at AAM meeting
February 15th 2023Cuban, of "Shark Tank' fame and owner of the Dallas Mavericks, called drugs prices ‘insane’ and used some profanity when talking pharmacy benefit managers at the annual meeting of the Association for Accessible Medicines yesterday. Cuban has co-founded an online pharmacy that he says will make drug prices lower and transparent.
Read More
Healthcare Trends That Could Make an Impact on Medical Practices in 2023
February 13th 2023Data collected from more than 40,000 practitioners revealed the top healthcare trends that will have the biggest impact on physicians and medical offices in 2023. Among them were patient-centric care, remote patient monitoring and mental healthcare.
Read More
Medicare Telehealth Services Remain Up In the Air Amid PHE Expiration
February 12th 2023Under the Consolidated Appropriations Act of 2023, some Medicare telehealth flexibilities will extend until December 31, 2024, though significant questions remain for the future of telehealth, especially in the Medicare program.
Watch
FDA Updates for the Week of Feb. 6, 2023
February 11th 2023The FDA has approved two pediatric indications this week: Takhyzro for hereditary angioedema and Eylea for retinopathy of prematurity. The agency expanded the label of Cibinqo for atopic dermatitis in adolescents, and granted full approval to Jemperli for endometrial cancer. Additionally, the agency has set PDUFA dates for two drugs: reproxalap for dry eye and zuranolone for depression.
Read More
Rich Priore Believes Investing in Public Health Can Bring Things Around Once PHE Expires
February 10th 2023Rich Priore, Sc.D., M.H.A., a clinical associate professor in the Department of Health Policy and Management at Tulane University, said if Americans invested in health prevention and wellness, fewer would be in hospitals and the cost of care would lower.
Watch
What’s on the Mind of Margaret “Meg” Murray of the Association for Community Affiliated Plans?
February 10th 2023Our guest on this month’s episode of the “What's on Your Mind” podcast is Margaret Murray, M.P.A., founding CEO of the Association for Community Affiliated Plans (ACAP) and a longtime member of Managed Healthcare Executive® editorial advisory board. Murray is an expert on Medicaid and healthcare policies that affect people with low incomes. In the interview with Managing Editor of MHE, Peter Wehrwein, she discusses ACAP’s growth and its legislative wins, Medicaid redetermination, “junk insurance,” and state Medicaid programs carving out pharmacy benefits.
Listen
The AMA, AHA and ANA Release PSA Urging Folks to Stay Updated on COVID-19 Vaccines
February 9th 2023Healthcare leaders are urging the public in a new public service announcement to make sure they are up-to-date on their COVID-19 vaccines, including the updated bivalent booster dose when eligible.
Read More